Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr Franke on Treatment Options for NSCLC Expressing Uncommon EGFR Mutations

April 10th 2023

Aaron J. Franke, MD, MS, discusses treatment options for patients with uncommon EGFR mutations in non–small cell lung cancer.

NCDB Analysis Shows Survival Benefit With Surgery vs Chemoradiation in NSCLC

April 10th 2023

Janeesh Sekkath Veedu, MBBS, discusses the need for research comparing outcomes with surgery-based treatment vs CRT and immunotherapy in stage IIIA NSCLC, shares findings from a NCDB analysis, and emphasizes the importance of continuing this research as updated data become available.

Dr Goldberg on Potential Strategies to Overcome Osimertinib Resistance in EGFR+ NSCLC

April 7th 2023

Sarah Goldberg, MD, MPH, discusses potential strategies to overcome osimertinib resistance in EGFR-positive metastatic non–small cell lung cancer.

Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management

April 6th 2023

Drs Mercado and Kovacs discuss the importance of multidisciplinary approaches to lung cancer screening and management, barriers to lung cancer screening that affect how early certain patients are diagnosed with this disease, and where the future of lung cancer detection and treatment is headed.

FDA Grants Fast Track Designation to SynKIR-110 for Mesothelioma

April 6th 2023

The FDA has granted a fast track designation to SynKIR-110 for the treatment of patients with mesothelioma.

Second-Line Liposomal Irinotecan Fails to Improve OS, PFS Over Topotecan in SCLC

April 6th 2023

Single-agent liposomal irinotecan resulted in a similar median overall survival and progression-free survival to that achieved with topotecan in patients with small cell lung cancer that had progressed on or following frontline platinum-based chemotherapy.

Cemiplimab With or Without Chemotherapy Provides Long-Term Clinical Benefit in Locally Advanced NSCLC

April 5th 2023

First-line cemiplimab monotherapy or in combination with platinum-based chemotherapy conferred long-term clinical benefit to patients with unresectable, locally advanced non–small cell lung cancer who were ineligible for concurrent chemoradiation.

Dr Sekkath Veedu on Survival Outcomes With Surgery vs Chemoradiation in Stage IIIA NSCLC

April 5th 2023

Janeesh Sekkath Veedu, MBBS, discusses the survival advantage conferred by surgical-based treatment compared with definitive chemoradiation in patients with stage IIIA non–small cell lung cancer.

Adagrasib Induces 68% ORR in Subset of Patients With KRAS G12C–Mutated NSCLC

April 4th 2023

Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance.

Atezolizumab Following Neoadjuvant Atezolizumab and Resection Improves DFS in NSCLC

April 4th 2023

Data for adjuvant atezolizumab following neoadjuvant atezolizumab and resection demonstrated an improvement in disease-free survival and a trend toward improved overall survival in patients with resectable stage IB to IIIB non–small cell lung cancer compared with those who did not receive adjuvant atezolizumab.

FDA Accepts sNDAs for Encorafenib and Binimetinib in BRAF V600E–Mutant NSCLC

April 4th 2023

The FDA has accepted for review supplemental new drug applications for the combination of encorafenib and binimetinib for the treatment of patients with metastatic non–small cell lung cancer harboring a BRAF V600E mutation, as detected by an FDA-approved test.

Eftilagimod Alpha/Pembrolizumab Generates Antitumor Activity in PD-1–Resistant NSCLC

April 3rd 2023

Treatment with eftilagimod alpha plus pembrolizumab resulted in tumor shrinkage and a tolerable safety profile in patients with anti–PD-1/PD-L1–resistant non–small cell lung cancer.

Dr Hassan on the CHRYSALIS trial of Amivantamab in EGFR Exon 20–Mutated NSCLC

April 3rd 2023

Khaled Hassan, MD, discusses key results from the phase 1 CHRYSALIS trial of the bispecific antibody amivantamab-vmjw in non–small cell lung cancer expressing EGFR exon 20 insertion mutations.

Atezolizumab/Cabozantinib Fails to Elicit Benefit Over SOC in Second-line Metastatic NSCLC

April 2nd 2023

Second-line atezolizumab plus cabozantinib did not generate a clinical benefit over standard-of-care docetaxel in patients with metastatic non–small cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy.

Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC

April 1st 2023

The combination of tusamitamab ravtansine and pembrolizumab with or without chemotherapy generated responses and was well tolerated when used as first-line treatment for patients with CEACAM5-positive nonsquamous non–small cell lung cancer.

Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases

March 31st 2023

Frontline cemiplimab plus chemotherapy improved overall survival and progression-free survival compared with investigator’s choice of chemotherapy for patients with PD-L1–positive non–small cell lung cancer that has metastasized to the brain.

Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC

March 31st 2023

The use of 4 cycles of chemotherapy plus durvalumab with or without tremelimumab-actl was associated with improved or sustained response and similar toxicity compared with chemotherapy alone as frontline therapy in patients with metastatic non–small cell lung cancer, according to post hoc exploratory findings from the phase 3 POSEIDON trial.

Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC

March 31st 2023

Taletrectinib continued to demonstrate meaningful efficacy in the form of a durable objective response rate and a high intracranial ORR with acceptable tolerability in both TKI-naïve and crizotinib-pretreated patients with ROS1-positive non–small cell lung cancer.

Dr Mitzman on the Use of Adjuvant Atezolizumab After Chemotherapy in Resectable NSCLC

March 30th 2023

Brian Mitzman, MD, FACS, FCCP, discusses the use of adjuvant atezolizumab following platinum-based chemotherapy in patients with resectable non–small cell lung cancer.

Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC

March 30th 2023

The addition of cemiplimab to platinum-doublet chemotherapy continued to provide a clinically meaningful and statistically significant improvement in clinical benefit over chemotherapy alone in patients with advanced non–small cell lung cancer, irrespective of histology or PD-L1 expression level.